Europe human insulin market accounted for $7.61 billion in 2019 and will grow by 7.06% annually over forecast years.
Highlighted with 37 tables and 56 figures, this 111-page report “Europe Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify Europe human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country.
Based on product type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Human Insulin Drugs
• Human Insulin Delivery Devices
Based on product, the Europe Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand)
• Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand)
Based on product, the Europe Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Syringes
• Pens (further segmented into Disposable, Reusable, Pen needles)
• Pumps
• Others
Based on application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes and Prediabetes
Based on distribution channel, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe (further segmented into Russia, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe human insulin market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players:
Astra Zeneca PLC
Biocon
Eli Lilly
Exir
Julphar
Novo Nordisk AS
Pfizer
Sanofi Aventis
Sedico
Wockhardt
(Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 10
1.2.1 Overview of Market Research Methodology 10
1.2.2 Market Assumption 11
1.2.3 Secondary Data 11
1.2.4 Primary Data 11
1.2.5 Data Filtration and Model Design 12
1.2.6 Market Size/Share Estimation 13
1.2.7 Research Limitations 14
1.3 Executive Summary 15
2 Market Overview and Dynamics 17
2.1 Market Size and Forecast 17
2.2 Major Growth Drivers 18
2.3 Market Restraints and Challenges 21
2.4 Emerging Opportunities and Market Trends 24
2.5 Porter’s Fiver Forces Analysis 27
3 Segmentation of Europe Market by Product Type 31
3.1 Market Overview by Product Type 31
3.2 Human Insulin Drugs 33
3.3 Human Insulin Delivery Devices 34
4 Segmentation of Europe Human Insulin Drugs Market by Drug Product 35
4.1 Market Overview by Drug Product 35
4.2 Modern Human Insulin 37
4.2.1 Modern Human Insulin by Type 39
4.2.2 Modern Human Insulin by Brand 42
4.3 Traditional Human Insulin 49
4.3.1 Traditional Human Insulin by Type 51
4.3.2 Traditional Human Insulin by Brand 54
5 Segmentation of Europe Human Insulin Delivery Devices Market by Device Product 57
5.1 Market Overview by Product 57
5.2 Syringes 59
5.3 Pens 60
5.4 Pumps 61
5.5 Other Devices 62
6 Segmentation of Europe Market by Application 63
6.1 Market Overview by Application 63
6.2 Type 1 Diabetes 65
6.3 Type 2 Diabetes 66
6.4 Gestational Diabetes and Prediabetes 67
7 Segmentation of Europe Market by Distribution Channel 68
7.1 Market Overview by Distribution Channel 68
7.2 Hospital Pharmacies 70
7.3 Retail Pharmacies 71
7.4 Online Pharmacies 72
8 European Market 2019-2026 by Country 73
8.1 Overview of European Market 73
8.2 Germany 76
8.3 UK 78
8.4 France 80
8.5 Spain 82
8.6 Italy 84
8.7 Rest of European Market 86
9 Competitive Landscape 88
9.1 Overview of Key Vendors 88
9.2 New Product Launch, Partnership, Investment, and M&A 92
9.3 Company Profiles 94
Astra Zeneca PLC 94
Biocon 96
Eli Lilly 97
Exir 98
Julphar 99
Novo Nordisk AS 100
Pfizer 101
Sanofi Aventis 102
Sedico 103
Wockhardt 104
10 Investing in Europe Market: Risk Assessment and Management 105
10.1 Risk Evaluation of Europe Market 105
10.2 Critical Success Factors (CSFs) 108
Related Reports and Products 111
Table 1. Snapshot of Europe Human Insulin Market, 2019-2026 16
Table 2. Main Product Trends and Market Opportunities in Europe Human Insulin Market 24
Table 3. Europe Human Insulin Market by Product Type, 2019-2026, $ mn 31
Table 4. Europe Human Insulin Drugs Market by Product, 2019-2026, $ mn 35
Table 5. Europe Human Insulin Drugs Market: Modern Human Insulin by Type, 2019-2026, $ mn 38
Table 6. Europe Human Insulin Drugs Market: Modern Human Insulin by Brand, 2019-2026, $ mn 38
Table 7. Europe Human Insulin Drugs Market: Traditional Human Insulin by Type, 2019-2026, $ mn 50
Table 8. Europe Human Insulin Drugs Market: Traditional Human Insulin by Brand, 2019-2026, $ mn 50
Table 9. Europe Human Insulin Delivery Devices Market by Product, 2019-2026, $ mn 57
Table 10. Europe Human Insulin Delivery Devices Market: Pens by Product, 2019-2026, $ mn 60
Table 11. Europe Human Insulin Market by Application, 2019-2026, $ mn 63
Table 12. Europe Human Insulin Market by Distribution Channel, 2019-2026, $ mn 68
Table 13. Europe Human Insulin Market by Country, 2019-2026, $ mn 75
Table 14. Germany Human Insulin Market by Product Type, 2019-2026, $ mn 77
Table 15. Germany Human Insulin Market by Application, 2019-2026, $ mn 77
Table 16. Germany Human Insulin Market by Distribution Channel, 2019-2026, $ mn 77
Table 17. UK Human Insulin Market by Product Type, 2019-2026, $ mn 79
Table 18. UK Human Insulin Market by Application, 2019-2026, $ mn 79
Table 19. UK Human Insulin Market by Distribution Channel, 2019-2026, $ mn 79
Table 20. France Human Insulin Market by Product Type, 2019-2026, $ mn 81
Table 21. France Human Insulin Market by Application, 2019-2026, $ mn 81
Table 22. France Human Insulin Market by Distribution Channel, 2019-2026, $ mn 81
Table 23. Spain Human Insulin Market by Product Type, 2019-2026, $ mn 83
Table 24. Spain Human Insulin Market by Application, 2019-2026, $ mn 83
Table 25. Spain Human Insulin Market by Distribution Channel, 2019-2026, $ mn 83
Table 26. Italy Human Insulin Market by Product Type, 2019-2026, $ mn 85
Table 27. Italy Human Insulin Market by Application, 2019-2026, $ mn 85
Table 28. Italy Human Insulin Market by Distribution Channel, 2019-2026, $ mn 85
Table 29. Human Insulin Market in Rest of Europe by Country, 2019-2026, $ mn 87
Table 30. Europe Human Insulin Market by Key Vendor, 2019, $ mn 90
Table 31. Astra Zeneca PLC: Company Snapshot 94
Table 32. Astra Zeneca PLC: Business Segmentation 94
Table 33. Astra Zeneca PLC: Product Portfolio 95
Table 34. Astra Zeneca PLC: Revenue, 2016-2018, $ mn 95
Table 35. Astra Zeneca PLC: Recent Developments 95
Table 36. Risk Evaluation for Investing in Europe Market, 2019-2026 106
Table 37. Critical Success Factors and Key Takeaways 109
